NCT05364892: ANCA

Biocollection of Patients With ANCA Associated Vasculitis

Recruiting now NA Last updated 7 August 2024

What this trial tests

NA trial testing Blood samples (80 mL) in ANCA-associated Vasculitis in 100 participants. Currently enrolling.

Timeline

27 October 2022

Primary endpoint
27 October 2032

27 October 2032

Quick facts

Lead sponsor	University Hospital, Brest
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	27 October 2022
Primary completion	27 October 2032
Estimated completion	27 October 2032
Sites	1 location across France

Drugs / interventions tested

• Blood samples (80 mL)
• Fecal samples — full drug profile →
• Urinary sample (20-40 mL)
• Questionnaires

Conditions studied

• ANCA-associated Vasculitis — all drugs for ANCA-associated Vasculitis →

Sponsor

University Hospital, Brest

Who can join

Adults 18 to 99, any sex, with ANCA-associated Vasculitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As rare disease, vasculitis affects a small number of patients, the cohorts available in the literature are few and the pathophysiological mechanisms remain to be elucidated. The collection of standardized data within a patientheque as part of a multi-year follow-up will facilitate the study of the characteristics of these diseases. This may, in particular, address the main objective of identifying predictors of relapse, as well as secondary objectives for predictive factors of mortality, infectious, cardiovascular or neoplastic complications that affect the prognosis of vasculitis in order to establish a more appropriate management of the patients concerned.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.